We have also found the combination of copanlisib and trastuzumab to be safe and well tolerated in a phase Ib clinical trial in patients with recurrent or metastatic HER2-positive breast cancer who are resistant to trastuzumab [46]. This evidence concerns the gene ERBB2 and breast cancer.